Copyright
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. May 26, 2019; 7(10): 1221-1229
Published online May 26, 2019. doi: 10.12998/wjcc.v7.i10.1221
Published online May 26, 2019. doi: 10.12998/wjcc.v7.i10.1221
Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report
Yan Zhang, Hui-Min Chen, Yong-Mei Liu, Feng Peng, Min Yu, Yong-Sheng Wang, You Lu, Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Wei-Ya Wang, Department of Pathology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Heng Xu, Precision Medicine Center, State Key Laboratory of Biotherapy, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Zhang Y and Chen HM contributed equally to this work; all authors contributed to the acquisition of data and writing and revision of this manuscript.
Supported by the National Natural Science Foundation of China , No. 81402561 .
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2013), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Yan Zhang, PhD, Doctor, Professor, Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, 37 Guoxue Lane, Chengdu 610041, Sichuan Province, China. zhang.yan@gmx.com
Telephone: +86-28-85422571 Fax: +86-28-85422571
Received: January 2, 2019
Peer-review started: January 4, 2019
First decision: January 27, 2019
Revised: February 19, 2019
Accepted: March 16, 2019
Article in press: March 16, 2019
Published online: May 26, 2019
Processing time: 145 Days and 19.5 Hours
Peer-review started: January 4, 2019
First decision: January 27, 2019
Revised: February 19, 2019
Accepted: March 16, 2019
Article in press: March 16, 2019
Published online: May 26, 2019
Processing time: 145 Days and 19.5 Hours
Core Tip
Core tip: This is a case report of T790M-related acquired drug resistant lung squamous cell cancer (LSCC) patient with good response to osimertinib, which indicated that T790M is also an important mechanism for acquired resistance in LSCC. In this case, the secondary T790M mutation of epidermal growth factor receptor (EGFR) was detected by next-generation sequencing (NGS) for frozen tissue but not detected by amplification refractory mutation system-polymerase chain reaction for formalin-fixed and paraffin-embedded sample, which suggests that NGS and better preservation conditions may contribute to higher sensitivity of EGFR T790M detection.